Akcea Therapeutics and Ambry Genetics have announced their expansion of their partnership in honor of the one-year anniversary of the hATTR Compass Genetic Testing Program, a no-cost, confidential genetic testing and confidential genetic counseling for patients who are clinically suspected of hereditary ATTR amyloidosis with polyneuropathy as well as individuals with a family history of hereditary ATTR amyloidosis. As part of their expanded partnership, Akcea and Ambry has increased their salesforce and marketing efforts to drive additional awareness and education for patients their families, caregivers and physicians.

Read the full press release here. If you have any questions, please don’t hesitate to reach out and email Akcea’s Patient Advocacy